---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224067"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-05-14T20:15:32+00:00"
generated_at: "2026-05-14T20:52:22.544429+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials

## Summary
- Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.
- Cash and investments $395.2M as of March 31, 2026; expected to fund operations through 2027.
- Enrollment completed in Phase 2 ZEPHYR trial (schizophrenia, n=307); topline data expected mid-August 2026.
- Last patient visit completed in Phase 2 IRIS trial (autism, n=161); topline data also expected mid-August 2026.
- Phase 2 VISTA trial for Alzheimer's disease psychosis ongoing; topline expected H2 2027.

## SEC filing metadata
- accession: 0001193125-26-224067
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-05-14T20:15:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/0001193125-26-224067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/mplt-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224067
- JSON: https://secwatch.observer/filing/0001193125-26-224067.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224067.txt

## Key facts
- Earnings Releases
  MapLight Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $60.7 million.
  - Period: first quarter ended March 31, 2026
  - Net income: Net loss was $60.7 million
  - Result: reported results
  source text: On May 14, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/0001193125-26-224067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.